Biotech Breakroom™

Industry Readiness Snapshot

Storia Therapeutics

Company: Storia Therapeutics
Founder: Dr. Avellaneda
BBR Code: BBR-416-808
Cohort / License: USD--001
License label: USD Classroom
Startup type: AI
Active Division: San Diego — AI
Active Divisions: 2
Operating Footprint: San Diego, North Carolina Biotech Triangle
Day: 443
Generated: 7/17/2026, 7:22:34 PM

Executive Snapshot

This section summarizes the official simulation outcome used for the Industry Readiness Snapshot.

Metric	Value
Company	Storia Therapeutics
Founder	Dr. Avellaneda
BBR Code	BBR-416-808
Cohort / License	USD--001
Startup type	AI
Active Division	San Diego — AI
Active Divisions	2
Operating Footprint	San Diego, North Carolina Biotech Triangle

Day / days survived	443
Ending Cash	$169,618,383
Valuation	$6,226,027,540
Net worth	$1,986,102,784
Employees	57
Products launched	13
Reputation	2,169
Data on hand	228,840
Total Company MRR	$2,224,487
Less: consolidated COGS	($1,564,343)
Consolidated Gross Profit	$660,144
Less: consolidated recurring operating expenses	($1,819,152)
Consolidated EBITDA	($1,159,008)
Runway now, based on recurring burn (months)	325.0
Founder Ownership	31.9%

Consolidated Company View

Consolidated Metric	Value
Total Company MRR	$2,224,487
Active Divisions	2
Consolidated EBITDA	($1,159,008)

Capital Position

This section separates spendable Operating Cash from allocated planning buckets and marketable investment assets.

Capital Category	Value
Operating Cash	$169,618,383
Allocated Cash	$282,333,651
Marketable Securities / Investment Assets	$20,153,911
Total Capital	$472,105,945

Allocated Cash Breakdown

Bucket	Value
Strategic Reserve	$102,000,000
R&D Allocation	$21,895,267
People Allocation	$20,703,264
Commercial Allocation	$22,485,000
Acquisition Reserve	$102,000,000
Investment Allocation	$13,250,120

Marketable Securities Breakdown

Asset	Value
Money Market / Cash Equivalents	$2,500,000
Treasury Securities	$3,250,000
BBR500	$2,189,569
IPO Holdings	$12,214,342

Capital by City

City	Operating Cash	Allocated Cash	Investment Assets	Total Capital
San Diego	$124,895,630	$221,383,320	$6,994,092	$353,273,042
North Carolina Biotech Triangle	$44,722,753	$60,950,331	$945,477	$106,618,561

Operating runway is calculated from Operating Cash. Allocated cash and investment assets are shown separately as part of the company's capital position.

Industry Readiness Profile

This section translates the simulation outcome into biotech industry-readiness signals. Ratings are based on the run data, not on AI-generated scoring.

Category	Rating	Interpretation
Capital Discipline	Developing	You maintained some financial flexibility, but the run still needed clearer conversion from cash into milestones, revenue, or funding leverage.
Milestone Velocity	Strong	The run converted product progress into market and investor-facing evidence. Strong milestone velocity requires more than valuation alone.
Commercial Traction	Strong	The company converted launched product work into meaningful recurring revenue.
Operating Efficiency / Burn Control	Developing	Revenue exists, but the company is still losing cash while scaling. Burn is about 0.5x current revenue.
Hiring / Resource Allocation	Developing	The team created operating

		capacity, but the report should be read through whether headcount translated into milestones, revenue, or runway leverage.
Ownership / Dilution Management	Needs Focus	Founder dilution became significant. This can be acceptable only if the capital clearly accelerates milestones, revenue, or survival.

Strategic Debrief

This section translates your simulation outcome into founder-level and industry-career language.

Debrief Area	Interpretation
Dominant strategy	Commercial traction strategy - the run emphasized launch, revenue, and customer adoption. Profitability and burn control should be judged separately from traction.
Main success driver	Commercial traction was the strongest driver. Product work translated into recurring revenue, even though burn control may still need separate attention.
Main bottleneck	Dilution was the main bottleneck. The company may have gained resources, but founder ownership and control weakened significantly.
What this means in industry	In industry, a product is not only judged by technical promise; it must also show customer demand, adoption, and commercial traction.

Startup Thesis / Market Research

This section summarizes the market context and product-thesis evidence used during the simulation. A generated report reflects simulation learning signals; it does not by itself certify startup success.

Field	Value
Market picked	AI
Core problem	Biotech R&D is slowed by inefficient data analysis and target identification, limiting discovery speed and accuracy.
TAM	$12B global biotech AI market
SAM	$4B AI-driven drug discovery segment
SOM	$400M initial obtainable market (~10% of SAM)
Demand	9/10
CAGR	20%
Competition	3/10
Validated solution / original thesis	Machine learning to identify novel therapeutic targets
Current product thesis	Machine learning to identify novel therapeutic targets
Final selected portfolio	Machine learning to identify novel therapeutic targets; Patient stratification algorithms using multi-omics data; AI-driven protein engineering platforms
Strongest customer-pull thesis	Machine learning to identify novel therapeutic targets
Strongest roadmap-progress thesis	Machine learning to identify novel therapeutic targets
Investor-preferred thesis	Machine learning to identify novel therapeutic targets

Customer discovery pattern	Distributed — one thesis showed the clearest relative pull, but customer interest was still spread across multiple options.
Leading thesis signal	4/10 interviews
Venture thesis	Build a AI company around Machine learning to identify novel therapeutic targets to address Biotech R&D is slowed by inefficient data analysis and target identification, limiting discovery speed and accuracy..

Sector Strategy / Pivot

Field	Value
Original sector	Therapeutics
Current sector	AI
Pivot count	1
Most recent pivot	Day 238, from Therapeutics to AI
Board interpretation	The company has a meaningful operating history and has substantially attempted the current strategy (95% attempt score). There is sustained negative net income in 5 of 6 recent periods, high competition pressure at the threshold level, and limited remaining MRR boost support. Although MRR remains above the $100K threshold and demand is not weak, the combination of these factors and the completion of multiple board goals under the current strategy justify approval of the pivot. No previous pivot has been used, so this is the first pivot approval.
Board confidence	85.0%
Player rationale	High competition pressure
Pivot cost	$3,986,292

Abandoned pipeline count	468

Final Product Portfolio

This section shows the final product theses selected after customer discovery. Customer pull and product-specific roadmap data are evidence signals, not automatic proof of market readiness.

Portfolio Slot	Product Thesis	Customer Pull	Product-Specific Roadmap Data	Status
Portfolio thesis 1	Machine learning to identify novel therapeutic targets	4/10 interviews	736,611	Portfolio thesis 1
Portfolio thesis 2	Patient stratification algorithms using multi-omics data	3/10 interviews	254,963	Portfolio thesis 2
Portfolio thesis 3	AI-driven protein engineering platforms	2/10 interviews	52,621	Portfolio thesis 3

Investor Scouting / Pro Forma Fit

This section summarizes how investor fit was evaluated. Investor interest is interpreted alongside customer pull, roadmap progress, pro forma quality, and dilution tradeoffs.

Field	Value
Current/prospective investor	Sovereign Biotech Fund
Investor fit	Strong
Investor-preferred thesis	Machine learning to identify novel therapeutic targets
Strongest customer-pull thesis	Machine learning to identify novel therapeutic targets

Strongest roadmap-progress thesis	Machine learning to identify novel therapeutic targets
Pro forma ask	Not submitted
Negotiation note	Most recent completed investor round is shown because no active investor negotiation is currently open.

Funding & Ownership History

Round	Day / Stage	Investor	Raised	Equity sold	Founder ownership after
1	44 / Angel / Seed	Garage Angel Syndicate	$4,000,000	10.6%	77.0%
2	150 / VC	Serious VC Fund B	$50,000,000	15.5%	51.5%
3	375 / IPO / Late-stage	Sovereign Biotech Fund	$900,000,000	14.6%	31.9%

Round 1 — Angel / Seed

Field	Value
Round number	1
Day closed	44
Stage / stage label	Angel / Seed
Investor name	Garage Angel Syndicate
Funding amount	$4,000,000
Equity sold	10.6%
Founder ownership after round	77.0%

Investor fit	Strong
Investor-preferred thesis	RNA interference drugs for metabolic disorders
Pro forma ask	$3,000,000

Round 2 — VC

Field	Value
Round number	2
Day closed	150
Stage / stage label	VC
Investor name	Serious VC Fund B
Funding amount	$50,000,000
Equity sold	15.5%
Founder ownership after round	51.5%
Investor fit	Strong
Investor-preferred thesis	RNA interference drugs for metabolic disorders
Pro forma ask	$50,000,000

Round 3 — IPO / Late-stage

Field	Value
Round number	3
Day closed	375
Stage / stage label	IPO / Late-stage
Investor name	Sovereign Biotech Fund

Funding amount	$900,000,000
Equity sold	14.6%
Founder ownership after round	31.9%
Investor fit	Strong
Investor-preferred thesis	Machine learning to identify novel therapeutic targets
Pro forma ask	Not provided

Current Ownership Snapshot

Field	Value
Founder ownership %	31.9%
Employee equity pool total	20.0%
Employee equity granted total	18.3%
Employee equity pool remaining	1.7%

Investor Ownership Split

Investor percentages below show the split within investor-held equity, not total company ownership.

Investor	Share of investor-held equity
Neighborhood Angel Dentist	68.3%
Garage Angel Syndicate	7.2%
Serious VC Fund B	11.7%
Sovereign Biotech Fund	12.7%

Company Performance Charts

These charts show global parent-company performance. When the company has multiple divisions, the financial trend lines use consolidated values rather than city-by-city views.

Financial / Operating Charts

Consolidated EBITDA trend



Cash Over Time



A large jump compressed the early values in the full chart, so an additional zoomed view is shown for readability.





Net Worth Over Time



A large jump compressed the early values in the full chart, so an additional zoomed view is shown for readability.





Employees Over Time



Market / Progress Charts

Valuation Over Time



A large jump compressed the early values in the full chart, so an additional zoomed view is shown for readability.



Reputation Over Time



Data Over Time

Total Company MRR Over Time

A large jump compressed the early values in the full chart, so an additional zoomed view is shown for readability.


1,500,000
1,000,000
500,000
0
100
200
300
Total
Comp...


6,000,000
4,000,000
2,000,000
0
380
400
420
440
Total
Comp...

Reflection + Career Translation

Use this section to prepare for the live offboarding discussion and to translate your simulation report into biotech industry-career language. This report summarizes performance signals from a run; certificate eligibility or workshop completion will be handled separately.

Reflection Prompts

1. What decision most improved your company's survival, valuation, or commercial traction?
2. What decision most damaged your runway, ownership, momentum, or strategic flexibility?
3. If this were a real biotech company, what would you do differently and why?

Career Translation

Professional summary you can adapt for interviews, LinkedIn, or career reflections:
Generated and analyzed a biotech industry-readiness simulation report covering startup runway, fundraising, hiring, product development, commercialization, equity dilution, and strategic decision-making under uncertainty.
Interview framing:
This simulation helped me understand how biotech companies connect scientific milestones to runway, financing, hiring, commercialization, product-market risk, and company survival.

Post-Offboarding Reflection

After the live cohort debrief, complete the post-offboarding Google Form. Your reflection helps measure whether the simulation improved biotech industry literacy, career decision-making, and startup-readiness.